Skip to main content

Table 2 ACE genotype and allele distributions among controls and migraine patients in a Norwegian population

From: Angiotensin-converting enzyme gene insertion/deletion polymorphism in migraine patients

   Genotypes Alleles
  N DD(%) ID(%) II(%) D(%) I(%)
Controls 403 92 (26.6) 204 (50.6) 107 (22.8) 388 (48.1) 418 (51.9)
Migraine 347 78 (22.5) 186 (53.6) 83 (23.9) 342 (49.3) 352 (50.7)
MwA subgroup 155 34 (21.9) 87 (56.1) 34 (21.9) 155 (50.0) 155 (50.0)
MoA subgroup 187 43 (23.0) 96 (51.3) 48 (25.7) 182 (48.7) 192 (51.3)
Lisinopril responders 12 2 (16.7) 6 (50.0) 4 (33.3) 10 (41.7) 14 (58.3)
Lisinopril non-responders 37 10 (27.0) 16 (43.2) 11 (29.7) 36 (48.6) 38 (51.4)
Candesartan responders* 18 7 (38.9) 9 (50.0) 2 (11.1) 23 (63.9) 13 (36.1)
Candesartan non-responders* 38 8 (21.1) 18 (47.4) 12 (31.6) 34 (44.7) 42 (55.3)
Responders combined 30 9 (30.0) 15 (50.0) 6 (20.0) 33 (55.0) 27 (45.0)
Non-responders combined 75 18 (24.0) 34 (45.3) 23 (30.7) 70 (46.7) 80 (53.3)
  1. * Response data available in 56 of 59 genotyped
  2. Allele and genotype frequency distributions are not significantly different for any diagnostic groups (migraine, MwA, MoA) vs controls, or for responders vs non-responders (p > 0.05).